Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Nisoldipine

FDA-approved product (tablet, extended release, oral), marketed as Nisoldipine, Sular.

Registered studies
6
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Nisoldipine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Hypertension

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Dihydropyridine derivatives
FDA pharmacologic class
Dihydropyridine Calcium Channel Blocker FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae16.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

6registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Nisoldipine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Nisoldipine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

    NCT04467931 · start 2020-01-19

    Registered record
    Registry ID
    NCT04467931
    Conditions
    Hypertension; COVID
    Interventions
    ACEI/ARB; Non-ACEI/ARB; ACEI; ARB
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-01-19
    Completion
    2020-12-31
    Enrolment
    22,213

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; COVID
    InterventionACEI/ARB; Non-ACEI/ARB; ACEI; ARB
    PhaseNot recorded
    Registry statusCompleted

  • Bioequivalence Study of Nisoldipine Extended-Release Tablets, 30 mg

    NCT00985660 · start 2007-06

    Registered record
    Registry ID
    NCT00985660
    Conditions
    Healthy
    Interventions
    Nisoldipine Extended-release Tablets, 30 mg; Sular® Extended Release Tablets, 30 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-06
    Completion
    2007-07
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionNisoldipine Extended-release Tablets, 30 mg; Sular® Extended Release Tablets, 30 mg
    PhasePhase 1
    Registry statusCompleted

  • Single-Dose Fed Bioequivalence Study of Nisoldipine Extended-Release Tablets (40 mg; Mylan) and Sular® Extended-Release Tablets (40 mg; First Horizon) in Healthy Volunteers

    NCT00979537 · start 2007-03

    Registered record
    Registry ID
    NCT00979537
    Conditions
    Healthy
    Interventions
    Nisoldipine Extended-release Tablets, 40 mg; Sular Tablets, 40 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-03
    Completion
    2007-03
    Enrolment
    83

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionNisoldipine Extended-release Tablets, 40 mg; Sular Tablets, 40 mg
    PhasePhase 1
    Registry statusCompleted

  • Fasting Bioequivalence Study of Nisoldipine Extended-Release Tablets 40 mg

    NCT00730197 · start 2007-02

    Registered record
    Registry ID
    NCT00730197
    Conditions
    Healthy
    Interventions
    Albuterol Sulfate Extended-Release Tablets 8 mg; VoSpire® ER Tablets 8 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-02
    Completion
    2007-03
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionAlbuterol Sulfate Extended-Release Tablets 8 mg; VoSpire® ER Tablets 8 mg
    PhasePhase 1
    Registry statusCompleted

  • Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension

    NCT00684489 · start 2003-09

    Registered record
    Registry ID
    NCT00684489
    Conditions
    Hypertension
    Interventions
    clinical hypertension specialist-no specific med. Any anti-hypertension meds.; renin guided therapeutics-no specific med. Any anti-hypertensive med.
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-09
    Completion
    2005-09
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventionclinical hypertension specialist-no specific med. Any anti-hypertension meds.; renin guided therapeutics-no specific med. Any anti-hypertensive med.
    PhaseNot applicable
    Registry statusCompleted

  • Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy

    NCT00311870 · start 1993-03

    Registered record
    Registry ID
    NCT00311870
    Conditions
    Diabetic Nephropathy
    Interventions
    nisoldipine; lisinopril
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    1993-03
    Completion
    1999-04
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Nephropathy
    Interventionnisoldipine; lisinopril
    PhasePhase 4
    Registry statusCompleted